Clinical Trials Browser

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03990896 2025-08-07

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06193525 2025-02-28

FUTURE

Phase 2 Recruiting

66 enrolled

Breast

Breast Neoplasms

NCT04690855 2023-12-04

TARA

Phase 2 Terminated

1 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03499353 2021-11-09

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2 Terminated

61 enrolled 63 charts

Breast

Breast Neoplasms

NCT04755868 2021-02-16

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Phase 2 Unknown

206 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02034916 2019-10-14

ABRAZO

Phase 2 Terminated

84 enrolled 21 charts

Breast

Breast Neoplasms

Clinical Trials

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

I-SPY

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

TNBC

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

PERSEVERE

FUTURE

TARA

ROME

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

ABRAZO